Document Detail


Multicentre comparative study of two schedules of gabexate mesilate in the treatment of acute pancreatitis. Italian Acute Pancreatitis Study Group.
MedLine Citation:
PMID:  11303975     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIM: To compare the efficacy of two different schedules of gabexate mesilate (900 mg/day, or 1,500 mg/day) in the treatment of severe acute pancreatitis. SETTING: Forty-two Italian medical and surgical centres took part in the study. STUDY DESIGN: A multicentre, prospective, open label, comparative, parallel-group, randomized study. METHODS: The patients enrolled in the study had acute pancreatitis as demonstrated by typical abdominal pain and baseline serum amylase concentrations more than twice the upper normal limit, findings compatible with acute pancreatitis at imaging techniques, and a Glasgow criteria score of > or =3. Patients were randomly assigned to one of the two schedules of treatment with gabexate mesilate being administered intravenously for at least 7 days. The minimum clinically relevant difference (delta), between groups, in incidence of complications due to acute pancreatitis, during the first month of the study treatment, was predefined as equal to 10%. RESULTS: A total of 199 patients were assigned to gabexate mesilate 900 treatment and 189 to gabexate mesilate 1,500. Complications developed in 88 patients within one month of beginning treatment 44/199: patients (22.1%) in the gabexate mesilate 900 group and 44/189 patients (23.3%) in the gabexate mesilate 1,500 group (difference 1.2%; 95% confidence interval: -7.2; 9.5%). CONCLUSIONS: Gabexate mesilate 900 mg per day is as effective as gabexate mesilate 1,500 mg per day in reducing the complications due to acute pancreatitis.
Authors:
R Pezzilli; M Miglioli
Related Documents :
21442665 - Traumatic bereavement, acute dissociation, and posttraumatic stress: 14 years after the...
18493355 - Endoscopic stenting and sphincterotomy of the minor papilla in symptomatic pancreas div...
17235705 - Octreotide/midodrine therapy significantly improves renal function and 30-day survival ...
23506675 - Morphometric of blastomeres in salmo salar.
7425355 - Hypothermia after cardiopulmonary bypass in man: amelioration by nitroprusside-induced ...
18387065 - Cost-effectiveness study comparing cefoperazone-sulbactam to a three-drug combination f...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver     Volume:  33     ISSN:  1590-8658     ISO Abbreviation:  Dig Liver Dis     Publication Date:    2001 Jan-Feb
Date Detail:
Created Date:  2001-04-16     Completed Date:  2001-07-12     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  100958385     Medline TA:  Dig Liver Dis     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  49-57     Citation Subset:  IM    
Affiliation:
Emergency Department, Sant'Orsola Hospital, Bologna, Italy. pezzilli@orsola-malpighi.med.unibo.it
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Disease
Aged
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Gabexate / administration & dosage*,  adverse effects
Humans
Male
Middle Aged
Pancreatitis / diagnosis,  drug therapy*,  etiology
Prospective Studies
Serine Proteinase Inhibitors / administration & dosage*,  adverse effects
Treatment Outcome
Chemical
Reg. No./Substance:
0/Serine Proteinase Inhibitors; 39492-01-8/Gabexate
Comments/Corrections
Comment In:
Dig Liver Dis. 2001 Jan-Feb;33(1):12-3   [PMID:  11303968 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study.
Next Document:  Antioxidant treatment in hereditary pancreatitis. A pilot study on three young patients.